ClinicalTrials.gg
CompletedNCT04062448Updated May 25, 2025Results posted

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

A Phase 2 interventional study of Ibrutinib and Rituximab in Waldenstrom Macroglobulinemia, sponsored by Janssen Pharmaceutical K.K.. Completed at 9 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia — 2 open to participants now, 7 under way, 2 of them phase 3. ibrutinib · Waldenstrom Macroglobulinemia.

Enrollment
21st of 25
16 · median 48
Started
2019
with 2 others
Phase 2
11 of 25
none open now
Registered
19th of 25
by date
Lead sponsor
1 of 25
Janssen Pharmaceutical K.K.

Among the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, this one is the 21st largest by enrollment, is one of 3 that started in 2019, is one of 11 in phase 2, and was the 19th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

2 of the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate overall response rate (ORR) by Independent Review Committee (IRC) assessment, when combined with rituximab in Japanese participants with treatment naïve or relapsed/refractory Waldenstrom's Macroglobulinemia (WM).

03

Conditions studied

  • Waldenstrom Macroglobulinemia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia (WM) in accordance with the consensus panel of the second International Workshop on Waldenstrom's Macroglobulinemia (IWWM)
  • Japanese participants with treatment naïve or WM
  • defined as serum monoclonal immunoglobulin M (IgM) greater than (>) 0.5 gram per deciliter (g/dL)
  • Symptomatic disease, requiring treatment
  • (ECOG) performance status of less than or equal to (\<=) 2
  • Hematology and biochemical values within protocol-defined limits
  • Female participants of must have a negative serum pregnancy test at screening and agree to use highly effective methods of while taking study drug. Women of childbearing potential must be practicing a highly effective, preferably user independent method of birth control during treatment with any drug in this study and for up to 12 months after the last dose of rituximab, 1 month after last dose of ibrutinib. Male participants must use an effective barrier method of contraception during the study and after receiving the last dose of ibrutinib, and for up to 12 months after last dose of rituximab if sexually active with a female of childbearing potential
  • Must sign an form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study. Participants must be willing and able to adhere to the prohibitions and restrictions specified in this protocol
  • Must be willing and able to adhere to the lifestyle restrictions specified in this protocol

Exclusion criteria

Exclusion Criteria:

  • Involvement of the central nervous system by WM
  • Prior exposure to ibrutinib or other Bruton's Tyrosine Kinase (BTK) inhibitors
  • Rituximab treatment within the last 12 months before the first dose of study intervention
  • Received any WM-related therapy \<=30 days prior to first administration of study treatment
  • Plasmapheresis less than (\<) 35 days prior to the initiation of study drug, except when at least one serum IgM central assessment was performed during the screening period and was >35 days from the most recent plasmapheresis procedure
  • History of other
  • Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
  • Infection requiring systemic treatment that was completed \<=14 days before the first dose of study drug
  • Currently active, Class B or C hepatic impairment
  • Inability or difficulty swallowing capsules, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function
  • Stroke or intracranial hemorrhage within 12 months prior to enrollment
  • Currently active, clinically significant cardiovascular disease
  • Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor
  • Infection with (HIV) or active infection with or virus
  • Major surgery within 4 weeks of first dose of study drug
  • Lactating or pregnant
  • Male participants who plan to father a child while enrolled in this study or within 3 months after the last dose of ibrutinib, and within 12 months after last dose of rituximab
  • Any to ibrutinib or rituximab including to the active substance or to any of the of ibrutinib or rituximab per local prescribing information
  • Received an intervention (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before the planned first dose of study intervention or is currently enrolled in an investigational study
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg [for example], compromise the wellbeing) or that could prevent, limit, or confound the protocol-specified assessments
  • Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Ibrutinib + Rituximab

    Participants will receive ibrutinib 420 milligram (mg) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity in combination with rituximab 375 milligram per square meter (mg/m\^2) intravenously (IV) on Day 1 of Weeks 1 to 4 and Weeks 17 to 20.

    Drug: Ibrutinib · Drug: Rituximab

Interventions

  • Ibrutinib 420 mg will be administered orally.

    Also known as: PCI-32765

  • Rituximab 375 mg/m\^2 will be administered intravenously.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) According to the Modified Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) Criteria

    ORR is defined as the percentage of participants achieving a best overall response of confirmed complete response (CR), very good partial response (VGPR) or partial response (PR) according to the modified sixth IWWM criteria (National Comprehensive Cancer Network \[NCCN\] version 2, 2019), as assessed by the Independent Review Committee (IRC). CR: Immunoglobulin M (IgM) in normal range, disappearance of monoclonal protein by immunofixation, no histologic evidence of bone marrow involvement, resolution of any adenopathy/organomegaly (if present at baseline) along with no signs or symptoms attributable to Waldenstrom's Macroglobulinemia (WM); VGPR and PR: greater than or equal to (\>=) 90 percent (%) (for VGPR) and \>=50% (for PR) reduction of serum IgM, decrease in adenopathy/organomegaly (if present at baseline) on physical examination or computerized tomography (CT) scan, no new symptoms or signs of active disease.

    Time frame: Up to 1 year 11 months

Secondary outcomes

  1. Progression Free Survival (PFS) Assessed by Independent Review Committee

    PFS was defined as duration from the date of initial dose of ibrutinib to the date of first documented evidence of disease progression or death, whichever occurred first regardless of the use of subsequent antineoplastic therapy prior to documented disease progression or death. Kaplan-Meier method was used for the analysis.

    Time frame: From the date of initial dose up to 3 years and 5 months

  2. Plasma Concentrations of Ibrutinib

    Plasma concentrations of ibrutinib were reported.

    Time frame: Day 1 of Week 4: Predose, 1 hour, 2 hours, 4 hours, and 6 hours postdose

  3. Plasma Concentrations of Metabolite PCI-45227

    Plasma concentrations of metabolite PCI-45227 were reported.

    Time frame: Day 1 of Week 4: Predose, 1 hour, 2 hours, 4 hours, and 6 hours postdose

  4. Number of Participants With Myeloid Differentiation Primary Response Gene 88 (MYD88) Biomarker Mutation

    Number of participants with MYD88 biomarker mutations were reported. MYD88 was assessed using next generation sequencing to detect the somatic mutations in the bone marrow aspiration samples collected during the study.

    Time frame: Day 1 of Week 1

  5. Number of Participants With C-X-C Chemokine Receptor Type 4 (CXCR-4) Biomarker Mutations

    Number of participants with CXCR-4 biomarker mutations were reported. CXCR-4 was assessed using next generation sequencing to detect the somatic mutations in the bone marrow aspiration samples collected during the study.

    Time frame: Day 1 of Week 1

  6. Number of Participants With Treatment- Emergent Adverse Events (TEAEs)

    An adverse event was defined as any untoward medical event that occurred in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs were defined as any AE that occurred at or after the initial administration of study intervention through the day of last dose plus 30 days.

    Time frame: From first dose of study drug up to 30 days post last dose of study drug (that is, up to 40.6 months)

07

Results

Posted Dec 1, 2022

Participant flow

Participant flow — Overall Study
MilestoneIbrutinib + Rituximab
Started16
Completed13
Not completed3
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryOverall Response Rate (ORR) According to the Modified Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) Criteria

ORR is defined as the percentage of participants achieving a best overall response of confirmed complete response (CR), very good partial response (VGPR) or partial response (PR) according to the modified sixth IWWM criteria (National Comprehensive Cancer Network \[NCCN\] version 2, 2019), as assessed by the Independent Review Committee (IRC). CR: Immunoglobulin M (IgM) in normal range, disappearance of monoclonal protein by immunofixation, no histologic evidence of bone marrow involvement, resolution of any adenopathy/organomegaly (if present at baseline) along with no signs or symptoms attributable to Waldenstrom's Macroglobulinemia (WM); VGPR and PR: greater than or equal to (\>=) 90 percent (%) (for VGPR) and \>=50% (for PR) reduction of serum IgM, decrease in adenopathy/organomegaly (if present at baseline) on physical examination or computerized tomography (CT) scan, no new symptoms or signs of active disease.

Time frame:
Up to 1 year 11 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) According to the Modified Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) Criteria
percentage of participantsIbrutinib + Rituximab
Overall Response Rate (ORR) According to the Modified Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) Criteria87.5
SecondaryProgression Free Survival (PFS) Assessed by Independent Review Committee

PFS was defined as duration from the date of initial dose of ibrutinib to the date of first documented evidence of disease progression or death, whichever occurred first regardless of the use of subsequent antineoplastic therapy prior to documented disease progression or death. Kaplan-Meier method was used for the analysis.

Time frame:
From the date of initial dose up to 3 years and 5 months
Reported as:
Median · months
Progression Free Survival (PFS) Assessed by Independent Review Committee
monthsIbrutinib + Rituximab
Progression Free Survival (PFS) Assessed by Independent Review CommitteeNA (NA to NA)
SecondaryPlasma Concentrations of Ibrutinib

Plasma concentrations of ibrutinib were reported.

Time frame:
Day 1 of Week 4: Predose, 1 hour, 2 hours, 4 hours, and 6 hours postdose
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Concentrations of Ibrutinib
nanograms per milliliter (ng/mL)Ibrutinib + Rituximab
Week 4: Predose4.10 ± 6.15
Week 4: 1 hour postdose55.6 ± 74.6
Week 4: 2 hours postdose94.9 ± 147
Week 4: 4 hours postdose89.9 ± 115
Week 4: 6 hours postdose50.5 ± 62.3
SecondaryPlasma Concentrations of Metabolite PCI-45227

Plasma concentrations of metabolite PCI-45227 were reported.

Time frame:
Day 1 of Week 4: Predose, 1 hour, 2 hours, 4 hours, and 6 hours postdose
Reported as:
Mean · ng/mL
Plasma Concentrations of Metabolite PCI-45227
ng/mLIbrutinib + Rituximab
Week 4: Predose13.7 ± 14.8
Week 4: 1 hour postdose39.9 ± 42.3
Week 4: 2 hours postdose63.9 ± 62.3
Week 4: 4 hours postdose79.6 ± 51.5
Week 4: 6 hour postdose65.6 ± 43.1
SecondaryNumber of Participants With Myeloid Differentiation Primary Response Gene 88 (MYD88) Biomarker Mutation

Number of participants with MYD88 biomarker mutations were reported. MYD88 was assessed using next generation sequencing to detect the somatic mutations in the bone marrow aspiration samples collected during the study.

Time frame:
Day 1 of Week 1
Reported as:
Count of participants · Participants
Number of Participants With Myeloid Differentiation Primary Response Gene 88 (MYD88) Biomarker Mutation
ParticipantsIbrutinib + Rituximab
Number of Participants With Myeloid Differentiation Primary Response Gene 88 (MYD88) Biomarker Mutation6
SecondaryNumber of Participants With C-X-C Chemokine Receptor Type 4 (CXCR-4) Biomarker Mutations

Number of participants with CXCR-4 biomarker mutations were reported. CXCR-4 was assessed using next generation sequencing to detect the somatic mutations in the bone marrow aspiration samples collected during the study.

Time frame:
Day 1 of Week 1
Reported as:
Count of participants · Participants
Number of Participants With C-X-C Chemokine Receptor Type 4 (CXCR-4) Biomarker Mutations
ParticipantsIbrutinib + Rituximab
Number of Participants With C-X-C Chemokine Receptor Type 4 (CXCR-4) Biomarker Mutations2
SecondaryNumber of Participants With Treatment- Emergent Adverse Events (TEAEs)

An adverse event was defined as any untoward medical event that occurred in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs were defined as any AE that occurred at or after the initial administration of study intervention through the day of last dose plus 30 days.

Time frame:
From first dose of study drug up to 30 days post last dose of study drug (that is, up to 40.6 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)
ParticipantsIbrutinib + Rituximab
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)16

Adverse events

Collected over All-cause mortality: From Baseline (Day 1) up to 41 months; Serious and other events: From first dose of study drug up to 30 days after last dose of study treatment ((that is, up to 40.6 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib + Rituximab0/16 (0%)4/16 (25%)16/16 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventIbrutinib + Rituximab
DehydrationMetabolism and nutrition disorders2/16
CellulitisInfections and infestations1/16
PneumoniaInfections and infestations1/16
Heat IllnessInjury, poisoning and procedural complications1/16
DehydrationMetabolism and nutrition disorders1/16
Arthritis BacterialInfections and infestations1/16
CellulitisInfections and infestations1/16
Covid-19Infections and infestations1/16
Escherichia BacteraemiaInfections and infestations1/16
PneumoniaInfections and infestations1/16
Most frequent other events
Showing 10 of 196
Most frequent other events
EventIbrutinib + Rituximab
RashSkin and subcutaneous tissue disorders6/16
Neutrophil Count DecreasedInvestigations5/16
RashSkin and subcutaneous tissue disorders5/16
PyrexiaGeneral disorders5/16
Neutrophil Count DecreasedInvestigations5/16
HypertensionVascular disorders5/16
PyrexiaGeneral disorders4/16
HypertensionVascular disorders4/16
Atrial FibrillationCardiac disorders4/16
ContusionInjury, poisoning and procedural complications4/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ibrutinib + Rituximab
Mean67.5 ± 11.21
Age, Customized
Age, Customized(Participants)Ibrutinib + Rituximab
Greater Than 6511
Less Than and Equal to (<=) 65 years5
Sex: Female, Male
Sex: Female, Male(Participants)Ibrutinib + Rituximab
Female4
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ibrutinib + Rituximab
Hispanic or Latino0
Not Hispanic or Latino16
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ibrutinib + Rituximab
American Indian or Alaska Native0
Asian16
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Ibrutinib + Rituximab
JAPAN16
08

Study locations

9 sites
  • Kameda Medical Center
    Chiba, 296-8602, Japan
  • National Cancer Center Hospital
    Chuo Ku, 104 0045, Japan
  • National Hospital Organization Kumamoto Medical Center
    Kumamoto City, 860 0008, Japan
  • Matsuyama Red Cross Hospital
    Matsuyama-City, 790-8524, Japan
  • Nagoya City University Hospital
    Nagoya City, 467 8602, Japan
  • Osaka Metropolitan University Hospital
    Osaka, 545 8586, Japan
  • Osaka University Hospital
    Suita-City, 565-0871, Japan
  • National Hospital Organization Disaster Medical Center
    Tachikawa, 190-0014, Japan
  • University of Tsukuba Hospital
    Tsukuba City, 305 8576, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Aug 2021, 22 months.

Results were first posted in Dec 2022, 1 year 3 months after primary completion.

Of 66 phase 2 interventional studies under Waldenstrom Macroglobulinemia, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 103. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2019
First posted
Aug 20, 2019
StartActual
Sep 25, 2019
Primary completionActual
Aug 24, 2021
CompletionActual
Mar 2, 2023
Results first posted
Dec 1, 2022
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04062448
Responsible party
Sponsor
First posted
Aug 20, 2019
Start date
Sep 25, 2019
Primary completion
Aug 24, 2021
Completion
Mar 2, 2023
Results posted
Dec 1, 2022
Last update
May 25, 2025

Study contacts

Janssen Pharmaceutical K.K., Japan Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Rituximab

Start the discussion